OncoMatch/Clinical Trials/NCT07150624
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
Is NCT07150624 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Experimental Group for hepatocellular carcinoma (hcc).
Treatment: Experimental Group — A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the operation, twice a day, and 930mg polyene phosphatidylcholine injection twice a day,combined with 100mg of magnesium isoglycyrrhizinate injection once a day,from the 1st to the 5th day after the operation. Compared with the monotherapy regimen of no liver protection treatment before the operation and receiving magnesium isoglycyrrhizinate injection 100mg once a day from the 1st to the 5th day after the operation.The efficacy and safety of treating postoperative liver function injury in patients undergoing laparoscopic hemihepatectomy for hepatocellular carcinoma were compared.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ASA 1–3
Prior therapy
Cannot have received: portal vein embolization
Cannot have received: tace
Cannot have received: systemic anti-tumor drug therapy
Cannot have received: liver-damaging treatment drugs
Cannot have received: systemic glucocorticoids
Lab requirements
Liver function
Child-Pugh grade A or B, with a score of ≤ 7; Preoperative ALT was less than 2 times the upper limit of normal; Preoperative ICG R15 was less than 10%; residual liver volume was more than 40% of the standard liver volume
Child-Pugh grade A or B, with a score of ≤ 7; Preoperative ALT was less than 2 times the upper limit of normal; Preoperative ICG R15 was less than 10%; residual liver volume was more than 40% of the standard liver volume
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify